The Innovative Hematopoietic Therapies division develops international translational research. His studies aim to develop new therapies for difficult-to-treat diseases such as Fanconi anemia, Dyskeratosis congenita or Diamond-Blackfan anemia. Among them, Fanconi Anemia stands out, in which a first international clinical trial of gene therapy is being carried out with a lentiviral vector developed in our laboratory.
On the other hand, based on the ability of mesenchymal stromal cells to facilitate tissue repair and control inflammation associated with various diseases, the Innovative Hematopoietic Therapies division is also interested in developing new cellular drugs based on the administration of these cells.
For more information, consult the Hematopoietic Innovative Therapies division website.